APPENDICES APPENDICES Cumulative indices for 2009 Author Index D Ingber M A Dahshan A 6(2), 143–144 Abdelhafiz AH 6(1), 83–91 Irons BK 6(4), 515–529 Deem S 6(4), 469–473 Acsadi G 6(3), 427–432 Ishii M 6(1), 41–50 Denktas AE 6(4), 589–593 Ammoury RF 6(3), 383–385 Iwasaki T 6(2), 231–237 Dieter RS 6(4), 589–593 Artés M 6(3), 427–432 Izquierdo I 6(3), 407–415 Dinis J 6(3), 417–425 Atala A 6(4), 595–602 J 6(2), 177–184 Djedid R Jiang H B 6(3), 351–370 6(1), 41–50 Basu S E Jurkiewicz D 6(4), 459–461 Eisen T 6(3), 417–425 Best C 6(1), 111–124 K 6(1), 75–81 Elez E Kamrava M Bhosle J 6(3), 321–333 6(3), 305–308 6(4), 553–568 F Khubchandani S Birenbaum DS Farbstein D 6(3), 371–380 6(4), 615–618 6(4), 531–538 Kiessling SJ Bland RM Feinstein JA 6(1), 51–63 6(1), 11–13 6(4), 541–543 Kim JJ Bogarin R Feldman TL 6(3), 309–320 6(1), 23–30 6(1), 15–22 Kiss R Bologna R Flomenhoft 6(3), 351–370 6(2), 133–134 6(1), 65–75 Klenha K 6(2), 145–149 Fonseca VA 6(3), 417–425 6(2), 165–175 6(4), 475–487 Koepke M Braun MS Fortea J 6(2), 145–149 6(2), 239–248 6(3), 407–415 Kowalski ML Brown SHM Friedman JH 6(3), 417–425 6(4), 515–529 6(2), 249–258 Kruszewski J Burke TA Fullhase C 6(3), 417–425 6(4), 595–602 6(2), 177–184 L Bush A G Larenas-Linnemann D 6(1), 31–39 Gecse K 6(2), 279–283 C 6(4), 603–613 Lefranc F Cameron AJ Goldman HB 6(3), 351–370 6(4), 489–496 6(2), 139–141 Levy AP Cameron DA Golomb J 6(4), 531–538 6(4), 553–568 6(2), 151–155 Lip GYH Capdevila J 6(2), 157–164 6(2), 187–189 6(3), 321–333 Gourley GR Lockley M Cappuzzo F 6(1), 75–81 6(1), 111–124 6(3), 335–350 Greidinger EL M Cerone J 6(3), 433–442 Ma L 6(2), 145–149 Gulley JL 6(4), 595–602 Chalmers LJ 6(3), 305–308 Macarulla T 6(1), 83–91 Gupta SK 6(3), 321–333 Chang V Mahller YY 6(2), 231–237 6(3), 297–299 6(2), 249–258 H Chanoine JP Makaryus AN Hall PS 6(1), 23–30 6(4), 497–505 6(4), 553–568 Chertin B Marsden AL Heise T 6(2), 151–155 6(4), 541–543 6(2), 209–229 6(2), 157–164 McFarlane SI Ho D Chishti A 6(4), 451–453 6(1), 99–103 6(1), 51–63 6(4), 497–505 Hosoda N Cripe TP 6(4), 507–513 6(4), 589–593 Metro G 6(3), 297–299 I Czuczman MS 6(3), 335–350 Ilany J 6(3), 371–380 Miller J 6(4), 455–457 6(1), 7–9 future science group www.futuremedicine.com 621 APPENDICES APPENDICES Mogensen CE Siddique A A 6(4), 467–468 6(2), 187–189 Ab42 Mor Y Singh R 6(2), 259–277 6(2), 151–155 6(4), 507–513 Abciximab 6(2), 157–164 Sivaswamy 6(3), 383–385 Mora S 6(1), 41–50 Adriamycin 6(3), 407–415 Small CB 6(3), 371–380 Moreira A 6(3), 393–406 6(4), 595–602 6(4), 595–602 Soler R Alemtuzumab Mulligan D 6(2), 177–184 6(3), 371–380 6(2), 165–175 Sowers JR 6(4), RUBAK N 6(4), 451–453 Aliskiren Nagireddy P Špičaková M 6(4), 497–505 6(4), 475–487 6(3), 417–425 Alosetron Nanjundappa A Stiegler RS 6(4), 603–613 6(3), 427–432 6(4), 489–496 Alvimopan Newell ML Surampudi PN 6(4), 603–613 6(1), 11–13 6(4), 475–487 Amiloride Nistala R Sweetenham JW 6(1), 51–63 6(4), 507–513 6(3), 291–292 Amlodipine Nonoda Y T 6(4), 515–529 6(4), 589–593 Tabernero J Amoxicillin Nowak D 6(3), 321–333 6(1), 65–75 6(3), 417–425 Takei K 6(2), 145–149 P 6(4), 589–593 6(3), 393–406 Palmer JS Tan T Ampicillin 6(2), 131–132 6(3), 427–432 6(2), 145–149 6(2), 133–134 Teper A AN1792 Peake MD 6(3), 393–406 6(2), 259–277 6(4), 569–575 Tolia Anthracycline Peer D 6(1), 1–2 6(4), 553–568 6(3), 293–296 6(1), 65–75 Apixaban Perez-Garcia J 6(1), 83–91 6(2), 187–189 6(3), 321–333 Trivedi S Aripiprazole Plazas MJ 6(3), 433–442 6(2), 249–258 6(3), 407–415 Twelves CJ Asimadoline R 6(2), 239–248 6(4), 603–613 Ramos FJ U Aspart 6(3), 321–333 Umpierrez GE 6(2), 209–229 Raposo J 6(4), 459–461 Aspirin 6(4), 595–602 V 6(2), 187–189 Rini BI Vasavada S Atenolol 6(3), 309–320 6(2), 209–229 6(1), 51–63 Rixe O Vernerová E 6(4), 515–529 6(3), 305–308 6(3), 417–425 Atorvastatin Robak T Vilsbøll T 6(2), 259–277 6(4), 577–587 6(2), 199–207 6(4), 475–487 Roger A W 6(4), 515–529 6(3), 407–415 Whaley-Connell A Axitinib Róka R 6(4), 507–513 6(1), 111–124 6(4), 603–613 Wisniewski T 6(3), 309–320 Rosh JR 6(4), 595–602 Azalastin 6(1), 15–22 Wittmann T 6(2), 279–283 Rossi 6(4), 603–613 B 6(1), 95–98 Y Bapineuzumab Ruiz-Echarri M Yeter E 6(2), 259–277 6(3), 321–333 6(3), 383–385 Beclomethasone dipropionate S Z 6(3), 393–406 Schliess F Zietkowski Z Bendamustine 6(2), 209–229 6(3), 417–425 6(4), 577–587 Seberová E Zimmet PZ Benztropine 6(3), 417–425 6(4), 489–496 6(2), 249–258 Shashidhar H Bevacimab 6(1), 65–75 Compound Index 6(3), 309–320 Shantsila E 5-fluorouracil Bevacizumab 6(2), 187–189 6(2), 239–248 6(1), 111–124 Shaw JE 6(3), 305–308 6(2), 239–248 6(4), 489–496 6(3), 321–333 6(3), 305–308 622 Therapy (2009) 6(4) future science group APPENDICES APPENDICES 6(3), 309–320 Chlorpromazine Deflux 6(3), 321–333 6(2), 249–258 6(2), 157–164 6(3), 335–350 Chlorpropamide Deferolimus 6(3), 351–370 6(4), 507–513 6(3), 321–333 Bexarotene Chlorthalidone Denileukin diftitox 6(3), 371–380 6(4), 515–529 6(3), 371–380 Bexxar Cholestyramine Dexamethasone 6(3), 371–380 6(1), 75–81 6(3), 371–380 Bleomycin Cilansetron 6(4), 595–602 6(4), 595–602 6(4), 603–613 Dextofisopam Bosutinib Cilengitide 6(4), 603–613 6(3), 321–333 6(3), 351–370 Diclofenac Bortezomib Cimetropium bromide 6(2), 259–277 6(3), 351–370 6(4), 603–613 Diltiazem Botulinum A toxin Cisplatin 6(4), 497–505 6(2), 131–132 6(3), 335–350 Dimebon 6(2), 133–134 6(3), 371–380 6(2), 259–277 6(2), 143–144 6(4), 569–575 Dimethyl sulfoxide 6(2), 157–164 Citalopram 6(2), 133–134 Botulinum toxin 6(4), 603–613 Ditropan 6(2), 139–141 Cladribine 6(2), 157–164 6(2), 133–134 6(4), 577–587 Donepezil 6(2), 177–184 Clarithromycin 6(2), 259–277 Budesonide 6(1), 65–75 Doxazosin 6(1), 31–39 6(2), 279–283 6(1), 51–63 6(2), 231–237 Clavulanate potassium 6(4), 497–505 6(3), 393–406 6(3), 393–406 Doxorubicin C Clavularate 6(4), 569–575 Calderol 6(2), 145–149 6(4), 595–602 6(1), 75–81 Clemastine Drisdol Camptosar 6(3), 417–425 6(1), 75–81 6(2), 239–248 Clioquinol Duloxetine Capecitabine 6(2), 259–277 6(4), 603–613 ® 6(2), 239–248 Clobazam Dysport 6(3), 305–308 6(4), 589–593 6(2), 165–175 6(3), 321–333 Clonidin E 6(4), 553–568 6(4), 603–613 Ebastine 6(4), 569–575 Clopidogrel 6(3), 407–415 Captopril 6(2), 187–189 EGb 761 6(4), 497–505 Clozapine 6(2), 259–277 6(4), 515–529 6(2), 249–258 Eloxatin Carbamazepine Colesevelam 6(2), 239–248 6(1), 41–50 6(4), 475–487 Enalapril Carboplatin Colostrinin 6(1), 51–63 6(3), 335–350 6(2), 259–277 Enoxaparin 6(3), 371–380 Corticosteroid 6(2), 187–189 6(4), 569–575 6(1), 31–39 Enzastaurin 6(4), 595–602 Cromolyn sodium 6(3), 351–370 Carmustine 6(2), 231–237 Epirubicin 6(3), 351–370 Cyclophosphamide 6(4), 595–602 6(3), 371–380 6(1), 99–103 Eptratuzumab CDX-110 6(3), 371–380 6(3), 371–380 6(3), 351–370 6(4), 577–587 Erlotinib Cediranib 6(4), 595–602 6(1), 51–63 6(3), 309–320 Cytarabine 6(1), 95–98 6(3), 321–333 6(3), 371–380 6(3), 321–333 6(3), 351–370 D 6(3), 335–350 Celecoxib Dabigatran 6(3), 351–370 6(2), 239–248 6(2), 187–189 6(4), 569–575 6(2), 259–277 Dacarbazine Etanercept Certican® 6(4), 595–602 6(2), 259–277 6(3), 351–370 Darifenacin Etoposide Cetilistat 6(2), 157–164 6(3), 371–380 6(1), 23–30 Dasatinib 6(3), 351–370 Cetuximab 6(3), 351–370 Everolimus 6(2), 239–248 6(3), 321–333 6(3), 309–320 6(3), 335–350 Daunorubicin 6(3), 321–333 6(3), 305–308 6(4), 569–575 6(3), 351–370 6(3), 321–333 6(3), 371–380 future science group www.futuremedicine.com 623 APPENDICES APPENDICES Ezitemide I M 6(4), 475–487 Ibritumomab Marimastat F 6(3), 371–380 6(3), 351–370 Fedotozine Ifosfamide Mebeverine 6(4), 603–613 6(3), 371–380 6(4), 603–613 Felodepine Imatinib Melphalan 6(4), 515–529 6(3), 291–292 6(3), 371–380 Fenofibrate 6(3), 309–320 Memantine 6(4), 469–473 6(3), 351–370 6(2), 259–277 6(4), 475–487 Indapamide Mepolizumab Fludarabine 694), 515–529 6(2), 231–237 6(4), 577–587 Indomethacin Metastat Flunisolide 6(2), 259–277 6(3), 351–370 6(3), 393–406 Infliximab Metformin Fluorouracil 6(1), 15–22 6(1), 23–30 6(1), 99–103 Insulin glulisine 6(2), 199–207 6(4), 595–602 6(2), 209–229 6(4), 475–487 Fluoropyrimidine Irbesartan 6(4), 489–496 6(3), 321–333 6(1), 51–63 6(4), 507–513 Fluoxetine Irinotecan 6(4), 515–529 6(4), 603–613 6(2), 239–248 6(4), 531–538 Fluphenazine 6(3), 305–308 Methotrexate 6(2), 249–258 6(3), 321–333 6(1), 99–103 Flurbiprofen 6(3), 351–370 6(4), 569–575 6(2), 259–277 6(4), 569–575 Methylnaltrexone Fluticasone Isotretinoin 6(4), 603–613 6(2), 231–237 6(3), 351–370 Metoprolol 6(3), 393–406 L 6(1), 51–63 Fluticasone furoate Labetalol Metronidazole 6(3), 393–406 6(1), 51–63 6(1), 65–75 Fluticasone propionate Lamotrigine Mitiglinide 6(3), 393–406 6(1), 41–50 6(4), 507–513 Folate/B6/B12 Lapatinib Mitomycin 6(2), 259–277 6(3), 351–370 6(3), 321–333 Folinic acid 6(4), 553–568 Mitoquinone 6(3), 305–308 Leucovorin 6(2), 259–277 Fostamatinib disodium 6(2), 239–248 Mizolastine 6(3), 371–380 6(3), 305–308 6(3), 417–425 G 6(3), 321–333 Mometasone furoate Galantamine Levetiracetam 6(3), 393–406 6(2), 259–277 6(1), 41–50 Mupirocin Galimberti D Lenalidomide 6(2), 279–283 6(2), 259–277 6(3), 371–380 N Gefitinib Linaclotide Naproxene 6(1), 95–98 6(4), 603–613 6(2), 259–277 6(3), 309–320 Liraglutide Nateglinide 6(3), 321–333 6(2), 199–207 6(4), 507–513 6(3), 335–350 Lisinopril Neomycin 6(3), 351–370 6(1), 51–63 6(4), 603–613 6(4), 569–575 6(4), 515–529 Nepadutant Gemcitabine Lispro 6(4), 603–613 6(3), 335–350 6(2), 259–277 Neutral protamine hagedorn 6(4), 569–575 Lonafarnib 6(2), 209–229 Gliclazide 6(3), 351–370 Nevirapine 6(4), 507–513 Loratadine 6(1), 11–13 Glimepiride 6(3), 417–425 Nexavar® 6(2), 199–207 Losartan see Sorafenib Granisetron 6(1), 51–63